Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LGD 6972

Next Previous
X
Search
Drug Profile

LGD 6972

Alternative Names: GCGR Antagonist Program - Ligand Pharmaceuticals; GRA; LGD-6972; LGD-6972 sodium salt; MB-11262; RVT-1502

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Metabasis Therapeutics
  • Developer Ligand Pharmaceuticals
  • Class Antihyperglycaemics; Small molecules; Sulfonic acids
  • Mechanism of Action Glucagon receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 07 Sep 2021 No development reported - Phase-II for Type 2 diabetes mellitus (Treatment-experienced) in USA (PO)
  • 06 May 2020 Ligand Pharmaceuticals regains license from Metavant Sciences
  • 30 Jul 2019 Metavant expects to make a decision regarding future development of RVT 1502 by end-2019

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top